SomnoMed Limited
SomnoMed Limited, together with its subsidiaries, produce and sells devices for the oral treatment of sleep related disorders in the Asia Pacific region, North America, and Europe. It provides SomnoDent Avant, as well as SomnoDent Classic, SomnoDent Flex, and SomnoDent Fusion are offered for the treatment of obstructive sleep apnea. The company also offers SomMorning Repositioner, a product desig… Read more
SomnoMed Limited (SOMNF) - Net Assets
Latest net assets as of June 2025: $46.39 Million USD
Based on the latest financial reports, SomnoMed Limited (SOMNF) has net assets worth $46.39 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($80.97 Million) and total liabilities ($34.58 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $46.39 Million |
| % of Total Assets | 57.29% |
| Annual Growth Rate | N/A |
| 5-Year Change | 44.26% |
| 10-Year Change | 41.92% |
| Growth Volatility | 41.06 |
SomnoMed Limited - Net Assets Trend (2004–2025)
This chart illustrates how SomnoMed Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for SomnoMed Limited (2004–2025)
The table below shows the annual net assets of SomnoMed Limited from 2004 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | $46.39 Million | +3.03% |
| 2024-06-30 | $45.02 Million | +100.97% |
| 2023-06-30 | $22.40 Million | -19.38% |
| 2022-06-30 | $27.79 Million | -13.59% |
| 2021-06-30 | $32.16 Million | -4.96% |
| 2020-06-30 | $33.84 Million | +89.87% |
| 2019-06-30 | $17.82 Million | -45.62% |
| 2018-06-30 | $32.77 Million | +5.86% |
| 2017-06-30 | $30.95 Million | -5.30% |
| 2016-06-30 | $32.69 Million | +51.98% |
| 2015-06-30 | $21.51 Million | +71.11% |
| 2014-06-30 | $12.57 Million | +8.61% |
| 2013-06-30 | $11.57 Million | +29.74% |
| 2012-06-30 | $8.92 Million | +43.47% |
| 2011-06-30 | $6.22 Million | +10.02% |
| 2010-06-30 | $5.65 Million | +30.40% |
| 2009-06-30 | $4.33 Million | -27.88% |
| 2008-06-30 | $6.01 Million | +53.55% |
| 2007-06-30 | $3.91 Million | +20.99% |
| 2006-06-30 | $3.23 Million | -55.09% |
| 2005-06-30 | $7.20 Million | +4598.70% |
| 2004-06-30 | $-160.08K | -- |
Equity Component Analysis
This analysis shows how different components contribute to SomnoMed Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7349427500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $119.96 Million | 258.59% |
| Other Comprehensive Income | $4.37 Million | 9.41% |
| Total Equity | $46.39 Million | 100.00% |
SomnoMed Limited Competitors by Market Cap
The table below lists competitors of SomnoMed Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
FIRST TIN PLC LS-001
F:1SN
|
$43.89 Million |
|
First Bankers Trustshares Inc
OTCQB:FBTT
|
$43.90 Million |
|
Signature Alliance Group Berhad
KLSE:0360
|
$43.91 Million |
|
Kukje Pharma Co Ltd
KO:002720
|
$43.92 Million |
|
Tifico Fiber Indonesia Tbk
JK:TFCO
|
$43.87 Million |
|
PRL Global Ltd
AU:PRG
|
$43.86 Million |
|
Sol Gel Technologies Ltd
NASDAQ:SLGL
|
$43.86 Million |
|
QS Energy Inc
PINK:QSEP
|
$43.86 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SomnoMed Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 45,024,195 to 46,390,473, a change of 1,366,278 (3.0%).
- Net loss of 3,456,329 reduced equity.
- Other comprehensive income decreased equity by 4,965,130.
- Other factors increased equity by 9,787,737.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-3.46 Million | -7.45% |
| Other Comprehensive Income | $-4.97 Million | -10.7% |
| Other Changes | $9.79 Million | +21.1% |
| Total Change | $- | 3.03% |
Book Value vs Market Value Analysis
This analysis compares SomnoMed Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.78x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-06-30 | $-0.05 | $0.39 | x |
| 2005-06-30 | $0.56 | $0.39 | x |
| 2006-06-30 | $0.24 | $0.39 | x |
| 2007-06-30 | $0.19 | $0.39 | x |
| 2008-06-30 | $0.16 | $0.39 | x |
| 2009-06-30 | $0.10 | $0.39 | x |
| 2010-06-30 | $0.12 | $0.39 | x |
| 2011-06-30 | $0.13 | $0.39 | x |
| 2012-06-30 | $0.17 | $0.39 | x |
| 2013-06-30 | $0.27 | $0.39 | x |
| 2014-06-30 | $0.28 | $0.39 | x |
| 2015-06-30 | $0.43 | $0.39 | x |
| 2016-06-30 | $0.63 | $0.39 | x |
| 2017-06-30 | $0.60 | $0.39 | x |
| 2018-06-30 | $0.65 | $0.39 | x |
| 2019-06-30 | $0.25 | $0.39 | x |
| 2020-06-30 | $0.51 | $0.39 | x |
| 2021-06-30 | $0.39 | $0.39 | x |
| 2022-06-30 | $0.34 | $0.39 | x |
| 2023-06-30 | $0.27 | $0.39 | x |
| 2024-06-30 | $0.37 | $0.39 | x |
| 2025-06-30 | $0.22 | $0.39 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SomnoMed Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -7.45%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -3.10%
- • Asset Turnover: 1.38x
- • Equity Multiplier: 1.75x
- Recent ROE (-7.45%) is above the historical average (-18.17%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 0.00% | -1978.89% | 0.05x | 0.00x | $-540.99K |
| 2005 | -45.36% | -866.20% | 0.05x | 1.10x | $-3.99 Million |
| 2006 | -129.49% | -234.52% | 0.44x | 1.26x | $-4.51 Million |
| 2007 | -83.68% | -144.03% | 0.48x | 1.20x | $-3.67 Million |
| 2008 | -45.45% | -74.66% | 0.52x | 1.17x | $-3.33 Million |
| 2009 | -41.97% | -22.75% | 1.32x | 1.39x | $-2.25 Million |
| 2010 | 13.91% | 7.15% | 1.40x | 1.39x | $221.08K |
| 2011 | 11.90% | 5.91% | 1.43x | 1.40x | $117.83K |
| 2012 | 6.22% | 3.42% | 1.25x | 1.46x | $-319.04K |
| 2013 | 5.16% | 3.18% | 1.01x | 1.61x | $-551.39K |
| 2014 | 3.29% | 1.34% | 1.58x | 1.55x | $-827.96K |
| 2015 | 2.80% | 1.73% | 1.24x | 1.30x | $-1.54 Million |
| 2016 | 0.50% | 0.37% | 1.09x | 1.22x | $-3.15 Million |
| 2017 | -10.38% | -6.78% | 1.20x | 1.28x | $-6.57 Million |
| 2018 | 6.41% | 4.42% | 1.15x | 1.27x | $-1.30 Million |
| 2019 | -0.22% | -0.07% | 1.69x | 1.95x | $-1.82 Million |
| 2020 | -3.31% | -1.95% | 0.93x | 1.82x | $-4.50 Million |
| 2021 | -3.71% | -1.90% | 1.12x | 1.75x | $-4.41 Million |
| 2022 | -15.97% | -6.11% | 1.25x | 2.09x | $-7.22 Million |
| 2023 | -35.70% | -9.57% | 1.34x | 2.79x | $-10.24 Million |
| 2024 | -27.19% | -13.36% | 1.31x | 1.55x | $-16.74 Million |
| 2025 | -7.45% | -3.10% | 1.38x | 1.75x | $-8.10 Million |
Industry Comparison
This section compares SomnoMed Limited's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SomnoMed Limited (SOMNF) | $46.39 Million | 0.00% | 0.75x | $43.88 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |